Amwell's second quarter arrived with the company halfway through the most consequential transition in its two-decade history: a legacy video-telehealth pioneer that rode the 2020 IPO boom to a $9 billion peak valuation is now a $215 million SaaS business that prints money in two of its three product lines and is one quarter from its first claimed year of positive operating cash flow. The headline says revenue fell 27% to $52.0 million. The ledgers tell a more interesting story. Subscription revenue - the line management has bet the company on - fell only 5% sequentially, and is now approaching half of total revenue, with the AMG (Amwell Medical Group) visit line flat to a year ago and the legacy services/Carepoint hardware line collapsing from $7.7 million to $1.9 million in a single year. That is not a uniform decline. It is a deliberate reshaping of the revenue mix toward the high-margin, multi-year contract business and away from the one-time services that defined the pandemic era. Adjusted EBITDA - the company's own scorecard - improved to a loss of $1.2 million from a loss of $4.7 million, and is now closer to break-even than at any point since the IPO; first-half operating cash flow flipped to a positive $9.7 million from a use of $29.8 million. The shape of the deterioration is changing, even as the top line still does.
The quarter also handed the market something it has not had to digest before: a 31%-of-revenue customer concentration (Elevance Health, disclosed in the most recent annual report) that puts the largest single client inside the company's pricing-and-renewal exposure, the wind-down of the Defense Health Agency contract by the third quarter of 2026 - a contract the FY2025 annual filing had already flagged as a going-concern-class risk - and a 20-day-old, mid-quarter change of independent auditor from PricewaterhouseCoopers to BDO. Each of these on its own would be a footnote; together they form a pattern. A company narrowing its business while shifting its audit relationship while watching two of its three largest customers near contract inflection is not a company in steady state. Management's claim of positive full-year operating cash flow in 2026 is the only number that matters until those three variables settle.
And then there is the part of the quarter that requires no interpretation. The stock closed at $10.42 on the earnings day of August 4, then ripped to $13.02 the next session, peaked at $13.58 on August 10, and traded at $12.65 on August 12 - roughly 21% above the earnings-day close and more than triple its November 2025 low of $3.78. Management did not buy stock; there is no repurchase program. The market is voting with price, and the vote is conditional on the fourth-quarter operating-cash-flow milestone the company reaffirmed. That is the single most important number to watch between now and the year-end print.